



(72) NAKAGAWA, Nobuaki, JP

(72) YASUDA, Hisataka, JP

(72) MORINAGA, Tomonori, JP

(71) SNOW BRAND MILK PRODUCTS CO., LTD., JP

(51) Int.Cl.⁶ C12N 15/19, C07K 14/52

(30) 1996/08/19 (235928/1996) JP

(54) **NOUVEAUX ADN ET PROCEDE DE PRODUCTION DE
PROTEINES A L'AIDE DE CES DERNIERS**

(54) **NOVEL DNAS AND PROCESS FOR PRODUCING PROTEINS BY
USING THE SAME**

(57) Cette invention concerne de nouveaux ADN qui correspondent aux listes de séquences 1 et 2. Cette invention concerne également un procédé de production de protéines, lequel consiste à insérer ces ADN dans des vecteurs d'expression de manière à produire des protéines qui possèdent des poids moléculaires d'environ 60 kD dans des conditions de réduction, et d'environ 60 à 120 kD dans des conditions de non-réduction. Ces protéines sont capables d'inhiber la formation d'ostéoclastes, et sont utiles dans le traitement de l'ostéoporose et des rhumatismes.

(57) DNAs represented by Sequence Listings (1 and 2) and a process for producing proteins which comprises inserting these DNAs into expression vectors to thereby produce proteins having molecular weights of about 60 kD (under reductive conditions) and about 60 kD and about 120 kD (under nonreductive conditions) and being capable of inhibiting the formation of osteoclasts. These proteins are useful in the treatment of osteoporosis and rheumatism.

ABSTRACT OF THE DISCLOSURE

DNAs having the nucleotide sequences of the Sequences No. 1 and No. 2 in the Sequence Table and a process for producing a protein which comprises inserting these DNAs into expression vectors to thereby produce a protein having molecular weights of about 60 kD (under reductive conditions) and about 60 kD and 120 kD (under non-reductive conditions) and being capable of inhibiting formation of osteoclast. These proteins are useful in the treatment of osteoporosis and rheumatism.

DESCRIPTION

NOVEL DNA AND PROCESS FOR PREPARING PROTEIN USING THE DNA

FIELD OF TECHNOLOGY

The present invention relates to a novel DNA and a process for preparing a protein which possesses an activity to inhibit osteoclast differentiation and/or maturation (hereinafter called osteoclastogenesis-inhibitory activity) by a genetic engineering technique using the DNA. More particularly, the present invention relates to a genomic DNA encoding a protein OCIF which possesses an osteoclastogenesis-inhibitory activity and a process for preparing said protein by a genetic engineering technique using the genomic DNA.

BACKGROUND OF THE INVENTION

Human bones are constantly repeating a process of resorption and formation. Osteoblasts controlling formation of bones and osteoclasts controlling resorption of bones take major roles in this process. Osteoporosis is a typical disease caused by abnormal metabolism of bones. This disease is caused when bone resorption by osteoclasts exceeds bone formation by osteoblasts. Although the mechanism of this disease is still to be elucidated completely, the disease causes the bones to ache, makes the bones fragile, and may results in fracturing of the bones. As the population of the aged increases, this disease results in an increase in bedridden aged people which becomes a social problem. Urgent development of a therapeutic agent for this disease is strongly desired. Disease due to a

decrease in bone mass is expected to be treated by controlling bone resorption, accelerating bone formation, or improving balance between bone resorption and formation.

Osteogenesis is expected to increase by accelerating proliferation, differentiation, or activation of the cells controlling bone formation, or by controlling proliferation, differentiation, or activation of the cells involved in bone resorption. In recent years, strong interest has been directed to physiologically active proteins (cytokines) exhibiting such activities as described above, and energetic research is ongoing on this subject. The cytokines which have been reported to accelerate proliferation or differentiation of osteoblasts include the proteins of fibroblast growth factor family (FGF: Rodan S. B. et al., Endocrinology vol. 121, p 1917, 1987), insulin-like growth factor I (IGF-I: Hock J. M. et al., Endocrinology vol. 122, p 254, 1988), insulin growth factor II (IGF-II: McCarthy T. et al., Endocrinology vol. 124, p 301, 1989), Activin A (Centrella M. et al., Mol. Cell. Biol., vol. 11, p 250, 1991), transforming growth factor- β , (Noda M., The Bone, vol. 2, p 29, 1988), Vasculotropin (Varonique M. et al., Biochem. Biophys. Res. Commun., vol. 199, p 380, 1994), and the protein of heterotopic bone formation factor family (bone morphogenic protein; BMP: BMP-2; Yanaguchi A. et al., J. Cell Biol. vol. 113, p 682, 1991, OP-1; Sampath T. K. et al., J. Biol. Chem. vol. 267, p 20532, 1992, and Knutson R. et al., Biochem. Biophys. Res. Commun. vol. 194, P 1352, 1993).

On the other hand, as the cytokines which suppress

differentiation and/or maturation of osteoclasts, transforming growth factor- β (Chenu C, et. al., Proc. Natl. Acad. Sci. USA, vol. 85, p 5683, 1988), interleukin-4 (Kasano K. et al., Bone-Miner., vol. 21, p 179, 1993), and the like have been reported. Further, as the cytokines which suppress bone resorption by osteoclast, calcitonin (Bone-Miner., vol. 17, p 347, 1992), macrophage colony stimulating factor (Hattersley G. et al., J. Cell. Physiol. vol. 137, p 199. 1988), interleukin-4 (Watanabe, K. et al., Biochem. Biophys. Res. Commun. vol. 172. P 1035, 1990), and interferon- γ (Gowen M. et al., J. Bone Miner. Res., vol. 1, p 46.9, 1986) have been reported.

These cytokines are expected to be used as agents for treating diseases accompanying bone loss by accelerating bone formation or suppressing of bone resorption. Clinical tests are being undertaken to verify the effect of improving bone metabolism of some cytokines such as insulin-like growth factor-I and the heterotopic bone formation factor family. In addition, calcitonin is already commercially available as a therapeutic agent for osteoporosis and a pain relief agent. At present, drugs for clinically treating bone diseases or shortening the period of treatment of bone diseases include activated vitamin D₃, calcitonin and its derivatives, and hormone preparations such as estradiol agent, ipriflavon or calcium preparations. These agents are not necessarily satisfactory in terms of the efficacy and therapeutic results. Development of a novel therapeutic agent which can be used in

place of these agents is strongly desired.

In view of this situation, the present inventors have undertaken extensive studies. As a result, the present inventors had found protein OCIF exhibiting an osteoclastogenesis-inhibitory activity in a culture broth of human embryonic lung fibroblast IMR-90 (ATCC Deposition No. CCL186), and filed a patent application (PCT/JP96/00374). The present inventors have conducted further studies relating to the origin of this protein OCIF exhibiting the osteoclastogenesis-inhibitory activity. The studies have matured into determination of the sequence of a genomic DNA encoding the human origin OCIF. Accordingly, an object of the present invention is to provide a genomic DNA encoding protein OCIF exhibiting osteoclastogenesis-inhibitory activity and a process for preparing this protein by a genetic engineering technique using the genomic DNA.

DISCLOSURE OF THE INVENTION

Specifically, the present invention relates to a genomic DNA encoding protein OCIF exhibiting osteoclastogenesis-inhibitory activity and a process for preparing this protein by a genetic engineering technique using the genomic DNA. The DNA of the present invention includes the nucleotide sequences No. 1 and No. 2 in the Sequence Table attached hereto.

Moreover, the present invention relates to a process for preparing a protein, comprising inserting a DNA including the nucleotide sequences of the sequences No. 1 and No. 2 in the Sequence Table into an expression vector, producing a vector

capable of expressing a protein having the following physicochemical characteristics and exhibiting the activity of inhibiting differentiation and/or maturation of osteoclasts, and producing this protein by a genetic engineering technique,

(a) molecular weight (SDS-PAGE):

(i) Under reducing conditions: about 60 kD,

(ii) Under non-reducing conditions: about 60 kD and about 120 kD;

(b) amino acid sequence:

includes an amino acid sequence of the Sequence ID No. 3 of the Sequence Table,

(c) affinity:

exhibits affinity to a cation exchanger and heparin, and

(d) thermal stability:

(i) the osteoclast differentiation and/or maturation inhibitory activity is reduced when treated with heat at 70°C for 10 minutes or at 56°C for 30 minutes,

(ii) the osteoclast differentiation and/or maturation inhibitory activity is lost when treated with heat at 90°C for 10 minutes.

The protein obtained by expressing the gene of the present invention exhibits an osteoclastogenesis-inhibitory activity. This protein is effective as an agent for the treatment and improvement of diseases involving decrease in the amount of bone such as osteoporosis, diseases relating to bone metabolism abnormality such as rheumatism, degenerative joint disease, or multiple myeloma, and is useful as an antigen to establish an

immunological diagnosis of such diseases.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 shows a result of Western Blotting analysis of the protein obtained by causing genomic DNA of the present invention to express a protein in Example 4 (iii), wherein lane 1 indicates a marker, lane 2 indicates the culture broth of COS7 cells in which a vector pWESR α OCIF (Example 4 (iii)) has been transfected, and lane 3 is the culture broth of COS7 cell in which a vector pWESR α (control) has been transfected.

BEST MODE FOR CARRYING OUT THE INVENTION

The genomic DNA encoding the protein OCIF which exhibits osteoclastogenesis-inhibitory activity in the present invention can be obtained by preparing a cosmid library using a human placenta genomic DNA and a cosmid vector and by screening this library using DNA fragments which are prepared based on the OCIF cDNA as a probe. The thus-obtained genomic DNA is inserted into a suitable expression vector to prepare an OCIF expression cosmid. A recombinant type OCIF can be obtained by transfecting the genomic DNA into a host organism such as various types of cells or microorganism strains and causing the DNA to express a protein by a conventional method. The resultant protein exhibiting osteoclastogenesis-inhibitory activity (an osteoclastogenesis-inhibitory factor) is useful as an agent for the treatment and improvement of diseases involving a decrease in bone mass such as osteoporosis and other diseases relating to bone metabolism abnormality and also as an antigen to prepare antibodies for establishing immunological diagnosis of such

diseases. The protein of the present invention can be prepared as a drug composition for oral or non-oral administration. Specifically, the drug composition of the present invention containing the protein which is an osteoclastogenesis-inhibitory factor as an active ingredient can be safely administered to humans and animals. As the form of drug composition, a composition for injection, composition for intravenous drip, suppository, nasal agent, sublingual agent, percutaneous absorption agent, and the like are given. In the case of the composition for injection, such a composition is a mixture of a pharmacologically effective amount of osteoclastogenesis-inhibitory factor of the present invention and a pharmaceutically acceptable carrier. The composition may further comprise amino acids, saccharides, cellulose derivatives, and other excipients and/or activation agents, including other organic compounds and inorganic compounds which are commonly added to a composition for injection. When an injection preparation is prepared using the osteoclastogenesis-inhibitory factor of the present invention and these excipients and activation agents, a pH adjuster, buffering agent, stabilizer, solubilizing agent, and the like may be added if necessary to prepare various types of injection agents.

The present invention will now be described in more detail by way of examples which are given for the purpose of illustration and not intended to be limiting of the present invention.

Example 1

<Preparation of a cosmid library>

A cosmid library was prepared using human placenta genomic DNA (Clonetech; Cat. No. 6550-2) and pWE15 cosmid vector (Stratagene). The experiment was carried out following principally the protocol attached to the pWE15 cosmid vector kit of Stratagene Company, provided Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory (1989)) was referred to for common procedures for handling DNA, E. coli, and phage.

(i) Preparation of restrictive enzymolysate of human-genomic DNA

Human placenta genomic DNA dissolved in 750 μ l of a solution containing 10 mM Tris-HCl, 10 mM MgCl₂, and 100 mM NaCl was added to four 1.5 ml Eppendorf tubes (tube A, B, C, and D) in the amount of 100 μ g each. Restriction enzyme MboI was added to these tubes in the amounts of 0.2 unit for tube A, 0.4 unit for tube B, 0.6 unit for tube C, and 0.8 unit for tube D, and DNA was digested for 1 hour. Then, EDTA in the amount to make a 20 mM concentration was added to each tube to terminate the reaction, followed by extraction with phenol/chloroform (1:1). A two-fold amount of ethanol was added to the aqueous layer to precipitate DNA. DNA was collected by centrifugation, washed with 70% ethanol, and DNA in each tube was dissolved in 100 μ l of TE (10 mM HCl (pH 8.0) + 1 mM EDTA buffer solution, hereinafter called TE). DNA in four tubes was combined in one tube and incubated for 10 minutes at 68°C. After cooling to room

temperature, the mixture was overlayed onto a 10%-40 % linear sucrose gradient which was prepared in a buffer containing 20 mM Tris-HCl (pH 8.0), 5 mM EDTA, and 1 mM NaCl in an centrifugal tube (38 ml). The tube was centrifuged at 26,000 rpm for 24 hours at 20°C using a rotor SRP28SA manufactured by Hitachi, Ltd. and 0.4 ml fractions of the sucrose gradient was collected using a fraction collector. A portion of each fraction was subjected to 0.4% agarose electrophoresis to confirm the size of DNA. Fractions containing DNA with a length of 30 kb (kilo base pair) to 40 kb were thus combined. The DNA solution was diluted with TE to make a sucrose concentration to 10% or less and 2.5-fold volumes of ethanol was added to precipitate DNA. DNA was dissolved in TE and stored at 4°C.

(ii) Preparation of cosmid vector

The pWE15 cosmid vector obtained from Stratagene Company was completely digested with restriction enzyme BamHI according to the protocol attached to the cosmid vector kit. DNA collected by ethanol precipitation was dissolved in TE to a concentration of 1 mg/ml. Phosphoric acid at the 5'-end of this DNA was removed using calf small intestine alkaline phosphatase, and DNA was collected by phenol extraction and ethanol precipitation. The DNA was dissolved in TE to a concentration of 1 mg/ml.

(iii) Ligation of genomic DNA to vector and in vitro packaging

1.5 micrograms of genomic DNA fractionated according to size and 3 µg of pWE15 cosmid vector which was digested with

restriction enzyme BamHI were ligated in 20 μ l of a reaction solution using Ready-To-Go T4DNA ligase of Pharmacia Company. The ligated DNA was packaged in vitro using GigapackTM II packaging extract (Stratagene) according to the protocol. After the packaging reaction, a portion of the reaction mixture was diluted stepwise with an SM buffer solution and mixed with E. coli XL1-Blue MR (Stratagene) which was suspended in 10 mM MgCl₂ to cause phage to infect, and plated onto LB agar plates containing 50 μ g/ml of ampicillin. The number of colonies produced was counted. The number of colonies per 1 μ l of packaging reaction was calculated based on this result.

(iv) Preparation of a cosmid library

The packaging reaction solution thus prepared was mixed with E. coli XL1-Blue MR and the mixture was plated onto agarose plates containing ampicillin so as to produce 50,000 colonies per agarose plate having a 15 cm of diameter. After incubating the plate overnight at 37°C, an LB culture medium was added in the amount of 3 ml per plate to suspend and collect colonies of E. coli. Each agarose plate was again washed with 3 ml of the LB culture medium and the washing was combined with the original suspension of E. coli. The E. coli collected from all agarose plates was placed in a centrifugal tube, glycerol was added to a concentration of 20%, and ampicillin was further added to make a final concentration of 50 μ g/ml. A portion of the E. coli suspension was removed and the remainder was stored at -80°C. The removed E. coli was diluted stepwise and plated onto an agar plates to count the number of colonies per 1 ml of

suspension.

Example 2

<Screening of cosmid library and purification of colony>

A nitrocellulose filter (Millipore) with a diameter of 14.2 cm was placed on each LB agarose plate with a diameter of 15 cm which contained 50 µg/ml of ampicillin. The cosmid library was plated onto the plates so as to produce 50,000 colonies of *E. coli* per plate, followed by incubation overnight at 37°C. *E. coli* on the nitrocellulose filter was transferred to another nitrocellulose filter according to a conventional method to obtain two replica filters. According to the protocol attached to the cosmid vector kit, cosmid DNA in the *E. coli* on the replica filters was denatured with an alkali, neutralized, and immobilized on the nitrocellulose filter using a Stratalinker (Stratagene). The filters were heated for two hours at 80°C in a vacuum oven. The nitrocellulose filters thus obtained were hybridized using two kinds of DNA produced, respectively, from 5'-end and 3'-end of human OCIF cDNA as probes. Namely, a plasmid was purified from *E. coli* pKB/OIF10 (deposited at The Ministry of International Trade and Industry, the Agency of Industrial Science and Technology, Biotechnology Laboratory, Deposition No. FERM BP-5267) containing OCIF cDNA. The plasmid containing OCIF cDNA was digested with restriction enzymes KpnI and EcoRI. Fragments thus obtained was separated using agarose gel electrophoresis. KpnI/EcoRI fragment with a length of 0.2 kb was purified using a QIAEX II gel extraction kit (Qiagen). This DNA was labeled with ³²p using the Megaprime DNA Labeling

System (Amasham) (5'-DNA probe). Apart from this, a BamHI/EcoRV fragment with a length of 0.2 kb which was produced from the above plasmid by digestion with restriction enzymes BamHI and EcoRV was purified and labeled with ^{32}p (3'-DNA probe). One of the replica filters described above was hybridized with the 5'-DNA probe and the other with the 3'-DNA probe. Hybridization and washing of the filters were carried out according to the protocol attached to the cosmid vector kit. Autoradiography detected several positive signals with each probe. One colony which gave positive signals with both probe was identified. The colony on the agar plate, which corresponding to the signal on the autoradiogram was isolated and purified. A cosmid was prepared from the purified colony by a conventional method. This cosmid was named pWEOCIF. The size of human genomic DNA contained in this cosmid was about 38 kb.

Example 3

<Determination of the nucleotide sequence of human OCIF genomic DNA>

(i) Subcloning of OCIF genomic DNA

Cosmid pWEOCIF was digested with restriction enzyme EcoRI. After the separation of the DNA fragments thus produced by electrophoresis using a 0.7% agarose gel, the DNA fragments were transferred to a nylon membrane (Hybond -N, Amasham) by the Southern blot technique and immobilized on the nylon membrane using Stratalinker (Stratagene). On the other hand, plasmid pBKOCIF was digested with restriction enzyme EcoRI and a 1.6

kb fragment containing human OCIF cDNA was isolated by agarose gel electrophoresis. The fragment was labeled with ^{32}P using the Megaprime DNA labeling system (Amasham).

Hybridization of the nylon membranes described above with the ^{32}P -labeled 1.6-kb OCIF cDNA was performed according to a conventional method detected that DNA fragments with a size of 6 kb, 4 kb, 3.6 kb, and 2.6 kb. These fragments hybridized with the human OCIF cDNA were isolated using agarose gel electrophoresis and individually subcloned into an EcoRI site of pBluescript II SK + vector (Strategene) by a conventional method. The resulting plasmids were respectively named pBSE 6, pBSE 4, pBSE 3.6, and PBSE 2.6.

(ii) Determination of the nucleotide sequence

The nucleotide sequence of human OCIF genomic DNA which was subcloned into the plasmid was determined using the ABI Dideoxy Terminator Cycle Sequencing Ready Reaction kit (Perkin Elmer) and the 373 Sequencing System (Applied Biosystems). The primer used for the determination of the nucleotide sequence was synthesized based on the nucleotide sequence of human OCIF cDNA (Sequence ID No. 4 in the Sequence Table). The nucleotide sequences thus determined are given as the Sequences No. 1 and No. 2 in the Sequence Table. The Sequence ID No. 1 includes the first exon of the OCIF gene and the Sequence ID No. 2 includes the second, third, fourth, and fifth exons. A stretch of about 17 kb is present between the first and second exons.

Example 4

<Production of recombinant OCIF using COS-7 cells>

(i) Preparation of OCIF genomic DNA expression cosmid

To express OCIF genomic DNA in animal cells, an expression unit of expression plasmid pcDL-SR α 296 (Molecular and Cellular Biology, vol. 8, P466-472, 1988) was inserted into cosmid vector pWE15 (Stratagene). First of all, the expression plasmid pcDL-SR α 296 was digested with a restriction enzyme Sal I to cut out expression unit with a length of about 1.7 kb which includes an SR α promotor, SV40 later splice signal, poly (A) addition signal, and so on. The digestion products were separated by agarose electrophoresis and the 1.7-kb fragment was purified using the QIAEX II gel extraction kit (Qiagen). On the other hand, cosmid vector pWE15 was digested with a restriction enzyme EcoRI and fragments were separated using agarose gel electrophoresis. pWE15 DNA of 8.2 kb long was purified using the QIAEX II gel extraction kit (Qiagen). The ends of these two DNA fragments were bluntled using a DNA blunting kit (Takara Shuzo), ligated using a DNA ligation kit (Takara Shuzo), and transferred into E. coli DH5 α (Gibco BRL). The resultant transformant was grown and the expression cosmid pWESR α containing an expression unit was purified using a Qiagen column (Qiagen).

The cosmid pWE OCIF containing the OCIF genomic DNA with a length of about 38 kb obtained in (i) above was digested with a restriction enzyme NotI to cut out the OCIF genomic DNA of about 38 kb. After separation by agarose gel electrophoresis, the DNA was purified using the QIAEX II gel extraction kit (Qiagen). On the other hand, the expression cosmid pWESR α was

digested with a restriction enzyme EcoRI and the digestion product was extracted with phenol and chloroform, ethanol-precipitated, and dissolved in TE.

pWESR α digested with a restriction enzyme EcoRI and an EcoRI-XmnI-NotI adapter (#1105, #1156 New England Biolaboratory Co.) were ligated using T4 DNA ligase (Takara Shuzo Co., Ltd.). After removal of the free adapter by agarose gel electrophoresis, the product was purified using QIAEX gel extraction kit (Qiagen). The OCIF genomic DNA with a length of about 37 kb which was derived from the digestion with restriction enzyme NotI and the pWESR α to which the adapter was attached were ligated using T4 DNA ligase (Takara Shuzo). The DNA was packaged in vitro using the Gigapack packaging extract (Stratagene) and infected with E. coli XL1-Blue MR (Stratagene). The resultant transformant was grown and the expression cosmid pWESR α OCIF which contained OCIF genomic DNA was inserted was purified using a Qiagen column (Qiagen). The OCIF expression cosmid pWESR α OCIF was ethanol-precipitated and dissolved in sterile distilled water and used in the following analysis.

(ii) Transient expression of OCIF genomic DNA and measurement of OCIF activity

A recombinant OCIF was expressed as described below using the OCIF expression cosmid pWESR α OCIF obtained in (i) above and its activity was measured. COS-7 (8×10^5 cells/well) cells (Riken Cell Bank, RCB0539) were planted in a 6-well plate using DMEM culture medium (Gibco BRL) containing 10% fetal bovine serum (Gibco BRL). On the following day, the culture

medium was removed and cells were washed with serum-free DMEM culture medium. The OCIF expression cosmid pWESR α OCIF which had been diluted with OPTI-MEM culture medium (Gibco BRL) was mixed with lipopfectamine and the mixture was added to the cells in each well according to the attached protocol. The expression cosmid pWESR α was added to the cells in the same manner as a control. The amount of the cosmid DNA and Lipopfectamine was respectively 3 μ g and 12 μ l. After 24 hours, the culture medium was removed and 1.5 ml of fresh EX-CELL 301 culture medium (JRH Bioscience) was added to each well. The culture medium was recovered after 48 hours and used as a sample for the measurement of OCIF activity. The measurement of OCIF activity was carried out according to the method described by Kumegawa, M. et al. (Protein, Nucleic Acid, and Enzyme, Vol. 34, p 999 (1989)) and the method of TAKAHASHI, N. et al. (Endocrinology vol. 122, p 1373 (1988)). The osteoclast formation in the presence of activated vitamin D₃ from bone marrow cells isolated from mice aged about 17 days was evaluated by the induction of tartaric acid resistant acidic phosphatase activity. The inhibition of the acid phosphatase was measured and used as the activity of the protein which possesses osteoclastogenesis-inhibitory activity (OCIF). Namely, 100 μ l/well of a OCIF sample which was diluted with α -MEM culture medium (Gibco BRL) containing 2×10^{-8} M activated vitamin D₃ and 10% fetal bovine serum was added to each well of a 96 well micro plate. Then, 3×10^5 bone marrow cells isolated from mice (about 17-days old) suspended in 100 μ l of α -MEM culture medium containing 10% fetal bovine serum

were added to each well of the 96 well micro plate and cultured for a week at 37°C and 100% humidity under 5% CO₂ atmosphere. On days 3 and 5, 160 µl of the conditioned medium was removed from each well, and 160 µl of a sample which was diluted with α -MEM culture medium containing 1×10^{-8} M activated vitamin D₃ and 10% fetal bovine serum was added. After 7 days from the start of culturing, the cells were washed with a phosphate buffered saline and fixed with a ethanol/acetone (1:1) solution for one minute at room temperature. The osteoclast formation was detected by staining the cells using an acidic phosphatase activity measurement kit (Acid Phosphatase, Leucocyte, Cat. No. 387-A, Sigma Company). A decrease in the number of cells positive to acidic phosphatase activity in the presence of tartaric acid was taken as the OCIF activity. The results are shown in Table 1, which indicates that the conditioned medium exhibits the similar activity to natural type OCIF obtained from the IMR-90 culture medium and recombinant OCIF produced by CHO cells.

TABLE 1

Activity of OCIF expressed by COS-7 cells in the conditioned medium

Dilution	1/10	1/20	1/40	1/80	1/160	1/320
OCIF genomic DNA introduced	++	++	++	++	+	-
Vector introduced	-	-	-	-	-	-
Untreated	-	-	-	-	-	-

"++" indicates an activity inhibiting 80% or more of osteoclast formation, "+" indicates an activity inhibiting 30-80% of osteoclast formation, and "-" indicates that no inhibition of osteoclast formation is observed.

(iii) Identification of the product by Western Blotting

A buffer solution (10 μ l) for SDS-PAGE (0.5 M Tris-HCl, 20% glycerol, 4% SDS, 20 μ g/ml bromophenol blue, pH 6.8) was added to 10 μ l of the sample for the measurement of OCIF activity prepared in (ii) above. After boiling for 3 minutes at 100°C, the mixture was subjected to 10% SDS polyacrylamide electrophoresis under non-reducing conditions. The proteins were transferred from the gel to a PVDF membrane (ProBlott, Perkin Elmer) using semi-dry blotting apparatus (Biorad). The membrane was blocked and incubated for 2 hours at 37°C together with a horseradish peroxidase-labeled anti-OCIF antibody obtained by labeling the previously obtained OCIF protein with horseradish peroxidase according to a conventional method. After washing, the protein which has bound the anti-OCIF antibody was detected using the ECL system (Amasham). As shown in Figure 1, two bands, one with a molecular weight of about 120 kilo dalton and the other 60 kilo dalton, were detected in

the supernatant obtained from the culture broth of COS-7 cells in which pWESR α OCIF was transfected. On the other hand, these two bands with a molecular weight of about 120 kilo dalton and 60 kilo dalton were not detected in the supernatant obtained from the culture broth of COS-7 cells in which pWESR α vector was transfected, confirming that the protein obtained was OCIF.

INDUSTRIAL APPLICABILITY

The present invention provides a genomic DNA encoding a protein OCIF which possesses an osteoclastogenesis-inhibitory activity and a process for preparing this protein by a genetic engineering technique using the genomic DNA. The protein obtained by expressing the gene of the present invention exhibits an osteoclastogenesis-inhibitory activity and is useful as an agent for the treatment and improvement of diseases involving a decrease in the amount of bone such as osteoporosis, other diseases resulting from bone metabolism abnormality such as rheumatism or degenerative joint disease, and multiple myeloma. The protein is further useful as an antigen to establish antibodies useful for an immunological diagnosis of such diseases.

NOTE ON MICROORGANISM

Depositing Organization:

The Ministry of International Trade and Industry, National
Institute of Bioscience and Human Technology, Agency of
Industrial Science and Technology

Address: 1-3, Higashi-1-Chome, Tsukuba-shi, Ibaraki-ken,
Japan

Date of Deposition: June 21, 1995 (originally deposited on
June 21, 1995 and transferred to the international
deposition according to the Budapest Treaty on
October 25, 1995)

Accession No. FERM BP-5267

TABLE OF SEQUENCES

Sequence number: 1

Length of sequence: 1316

Sequence Type: nucleic acid

Strandedness: double

Topology: linear

Molecular type: genomic DNA (human OCIF genomic DNA-1)

Sequence:

```

CTGGAGACAT ATAAC TTGAA CACTTGGCCC TGATGGGGAA GCAGCTCTGC AGGGACTTTT 60
TCAGCCATCT GTAAACAATT TCAGTGCCAA CCGGCGAACT GTAATCCATG AATGGGACCA 120
CACTTTACAA GTCATCAAGT CTAAC TTCTA GACCAGGGAA TTAATGGGGG AGACAGCGAA 180
CCCTAGAGCA AAGTGCCAAA CTTCTGTCTA TAGCTTGAGG CTAGTGGAAG GACCTCGAGG 240
AGGCTACTCC AGAAGTTCAG CGCGTAGGAA GCTCCGATAC CAATAGCCCT TTGATGATGG 300
TGGGGTTGGT GAAGGGAACA GTGCTCCGCA AGGTTATCCC TGGCCCAGGC AGTCCAATTT 360
TCACTCTGCA GATTCTCTCT GGCTCTAACT ACCCCAGATA ACAAGGAGTG AATGCAGAAT 420
AGCACGGGCT TTAGGGCCAA TCAGACATTA GTTAGAAAAA TTCCTACTAC ATGGTTTATG 480
TAAAC TTGAA GATGAATGAT TCGGAAC TCC CCGAAAAGGG CTCAGACAAT GCCATGCATA 540
AAGAGGGGCC CTGTAATTTG AGGTTTCAGA ACCCGAAGTG AAGGGGTCAG GCAGCCGGGT 600
ACGGCGGAAA CTCACAGCTT TCGCCCAGCG AGAGGACAAA GGTCTGGGAC ACACTCCAAC 660
TGCGTCCGGA TCTTGGCTGG ATCGGACTCT CAGGGTGGAG GAGACACAAG CACAGCAGCT 720
GCCCAGCGTG TGGCCAGCCC TCCCACCGCT GGTCCCGGCT GCCAGGAGGC TGGCCGCTGG 780
CGGGAAGGGG CCGGGAAACC TCAGAGCCCC GCGGAGACAG CAGCCGCCCT GTTCCTCAGC 840
CCGGTGGCTT TTTTTCCTCC TGCTCTCCCA GGGGACAGAC ACCACCGCCC CACCCCTCAC 900
GCCCCACCTC CCTGGGGGAT CCTTTCGGCC CCAGCCCTGA AAGCGTTAAT CCTGGAGCTT 960
TCTGCACACC CCCCAGCCGC TCCCGCCCAA GCTTCCTAAA AAAGAAAGGT GCAAAGTTTG 1020
GTCCAGGATA GAAAAATGAC TGATCAAAGG CAGGCGATAC TTCCTGTTGC CGGGACGCTA 1080
TATATAACGT GATGACGCA CGGGCTGCGG AGACGCACCG GAGCGCTCGC CCAGCCGCCG 1140

```

CCTCCAAGCC CCTGAGGTTT CCGGGGACCA CA ATG AAC AAG TTG CTG TGC TGC 1193

Met Asn Lys Leu Leu Cys Cys

-20

-15

GCG CTC GTG GTAAGTCCCT GGGCCAGCCG ACGGGTGCCC GCGCCTGGG 1242

Ala Leu Val

GAGGCTGCTG CCACCTGGTC TCCCAACCTC CCAGCGGACC GCGGGGAGA AGGCTCCACT 1302

CGCTCCCTCC CAGG 1316

Sequence number: 2

Length of sequence: 9898

Sequence Type: nucleic acid

Strandedness: double

Topology: linear

Molecular type: genomic DNA (human OCIF genomic DNA-2)

Sequence:

GCTTACTTTG TGCCAAATCT CATTAGGCTT AAGGTAATAC AGGACTTTGA GTCAAATGAT 60

ACTGTTGCAC ATAAGAACAA ACCTATTTTC ATGCTAAGAT GATGCCACTG TGTTCCCTTC 120

TCCTTCTAG TTT CTG GAC ATC TCC ATT AAG TGG ACC ACC CAG GAA ACG TTT 171

Phe Leu Asp Ile Ser Ile Lys Trp Thr Thr Gln Glu Thr Phe

-10

-5

1

CCT CCA AAG TAC CTT CAT TAT GAC GAA GAA ACC TCT CAT CAG CTG TTG 219

Pro Pro Lys Tyr Leu His Tyr Asp Glu Glu Thr Ser His Gln Leu Leu

5

10

15

TGT GAC AAA TGT CCT CCT GGT ACC TAC CTA AAA CAA CAC TGT ACA GCA 267
 Cys Asp Lys Cys Pro Pro Gly Thr Tyr Leu Lys Gln His Cys Thr Ala
 20 25 30 35

AAG TGG AAG ACC GTG TGC GCC CCT TGC CCT GAC CAC TAC TAC ACA GAC 315
 Lys Trp Lys Thr Val Cys Ala Pro Cys Pro Asp His Tyr Tyr Thr Asp
 40 45 50

AGC TGG CAC ACC AGT GAC GAG TGT CTA TAC TGC AGC CCC GTG TGC AAG 363
 Ser Trp His Thr Ser Asp Glu Cys Leu Tyr Cys Ser Pro Val Cys Lys
 55 60 65

GAG CTG CAG TAC GTC AAG CAG GAG TGC AAT CGC ACC CAC AAC CGC GTG 411
 Glu Leu Gln Tyr Val Lys Gln Glu Cys Asn Arg Thr His Asn Arg Val
 70 75 80

TGC GAA TGC AAG GAA GGG CGC TAC CTT GAG ATA GAG TTC TGC TTG AAA 459
 Cys Glu Cys Lys Glu Gly Arg Tyr Leu Glu Ile Glu Phe Cys Leu Lys
 85 90 95

CAT AGG AGC TGC CCT CCT GGA TTT GGA GTG GTG CAA GCT G GTACGTGTCA 509
 His Arg Ser Cys Pro Pro Gly Phe Gly Val Val Gln Ala
 100 105 110

ATGTGCAGCA AAATTAATTA GGATCATGCA AAGTCAGATA GTTGTGACAG TTTAGGAGAA 569

CACTTTTGTT CTGATGACAT TATAGGATAG CAAATTGCAA AGGTAATGAA ACCTGCCAGG 629
 TAGGTACTAT GTGTCTGGAG TGCTTCCAAA GGACCATTGC TCAGAGGAAT ACTTTGCCAC 689
 TACAGGGCAA TTTAATGACA AATCTCAAAAT GCAGCAAATT ATTCTCTCAT GAGATGCATG 749
 ATGGTTTTTT TTTTTTTTTT TAAAGAAACA AACTCAAGTT GCACTATTGA TAGTTGATCT 809
 ATACCTCTAT ATTTCACTTC AGCATGGACA CCTTCAAAC TGCAGCACTTT TTGACAAACA 869
 TCAGAAATGT TAATTTATAC CAAGAGAGTA ATTATGCTCA TATTAATGAG ACTCTGGAGT 929
 GCTAACAATA AGCAGTTATA ATTAATTATG TAAAAAATGA GAATGGTGAG GGGAAATTGCA 989
 TTTCATTATT AAAACAAGG CTAGTTCTTC CTTTAGCATG GGAGCTGAGT GTTTGGGAGG 1049
 GTAAGGACTA TAGCAGAATC TCTTCAATGA GCTTATTCTT TATCTTAGAC AAAACAGATT 1109
 GTCAAGCCAA GAGCAAGCAC TTGCCTATAA ACCAAGTGCT TTCTCTTTTG CATTTTGAAC 1169
 AGCATTGGTC AGGGCTCATG TGTATTGAAT CTTTTAAACC AGTAACCCAC GTTTTTTTTC 1229
 TGCCACATTT GCGAAGCTTC AGTGCAGCCT ATAACTTTTT ATAGCTTGAG AAAATTAAGA 1289
 GTATCCACTT ACTTAGATGG AAGAAGTAAT CAGTATAGAT TCTGATGACT CAGTTTGAAG 1349
 CAGTGTCTCT CAACTGAAGC CCTGCTGATA TTTTAAGAAA TATCTGGATT CCTAGGCTGG 1409
 ACTCCTTTTT GTGGGCAGCT GTCCTGCGCA TTGTAGAATT TTGGCAGCAC CCCTGCACTC 1469
 TAGCCACTAG ATACCAATAG CAGTCCTTCC CCCATGTGAC AGCCAAAAT GTCTTCAGAC 1529
 ACTGTCAAAT GTCGCCAGGT GGCAAAATCA CTCCTGGTTG AGAACAGGGT CATCAATGCT 1589
 AAGTATCTGT AACTATTTTA ACTCTCAAAA CTTGTGATAT ACAAAGTCTA AATTATTAGA 1649
 CGACCAATAC TTTAGGTTTA AAGGCATACA AATGAAACAT TCAAAAATCA AAATCTATTC 1709
 TGTTTCTCAA ATAGTGAATC TTATAAAATT AATCACAGAA GATGCAAATT GCATCAGAGT 1769
 CCCTTAAAAT TCCTCTTCGT ATGAGTATTT GAGGGAGGAA TTGGTGATAG TTCCTACTTT 1829
 CTATTGGATG GTACTTTGAG ACTCAAAGC TAAGCTAAGT TGTGTGTGTG TCAGGGTGCG 1889
 GGGTGTGGAA TCCCATCAGA TAAAAGCAAA TCCATGTAAT TCATTCAGTA AGTTGTATAT 1949
 GTAGAAAAAT GAAAAGTGGG CTATGCAGCT TCGAAACTAG AGAATTTTGA AAAATAATGG 2009
 AAATCACAAG GATCTTTCTT AAATAAGTAA GAAAATCTGT TTGTAGAATG AAGCAAGCAG 2069
 GCAGCCAGAA GACTCAGAAC AAAAGTACAC ATTTTACTCT GTGTACACTG GCAGCACAGT 2129

GGGATTTATT TACCTCTCCC TCCCTAAAAA CCCACACAGC GGTTCCTCTT GGGAAATAAG 2189
AGGTTTCCAG CCCAAAGAGA AGGAAAGACT ATGTGGTGTT ACTCTAAAAA GTATTTAATA 2249
ACCGTTTTGT TGTGCTGTT GCTGTTTTGA AATCAGATTG TCTCCTCTCC ATATTTTATT 2309
TACTTCATTC TGTTAATTCC TGTGGAATTA CTTAGAGCAA GCATGGTGAA TTCTCAACTG 2369
TAAAGCCAAA TTTCTCCATC ATTATAATTT CACATTTTGC CTGGCAGGTT ATAATTTTTA 2429
TATTTCCACT GATAGTAATA AGGTAAAATC ATTACTTAGA TGGATAGATC TTTTTCATAA 2489
AAAGTACCAT CAGTTATAGA GGAAGTCAT GTTCATGTTT AGGAAGGTCA TTAGATAAAG 2549
CTTCTGAATA TATTATGAAA CATTAGTTCT GTCATTCTTA GATTCTTTTT GTTAAATAAC 2609
TTTAAAAGCT AACTTACCTA AAAGAAATAT CTGACACATA TGAAGTCTC ATTAGGATGC 2669
AGGAGAAGAC CCAAGCCACA GATATGTATC TGAAGAATGA ACAAGATTCT TAGGCCCCGGC 2729
ACGGTGGCTC ACATCTGTAA TCTCAAGAGT TTGAGAGGTC AAGCGGGCA GATCACCTGA 2789
GGTCAGGAGT TCAAGACCAG CCTGGCCAAC ATGATGAAAC CCTGCCTCTA CTAAAAATAC 2849
AAAAATTAGC AGGGCATGGT GGTGCATGCC TGCAACCCTA GCTACTCAGG AGGCTGAGAC 2909
AGGAGAATCT CTTGAACCTT CGAGGCGGAG GTTGTGGTGA GCTGAGATCC CTCTACTGCA 2969
CTCCAGCCTG GGTGACAGAG ATGAGACTCC GTCCCTGCCG CCGCCCCCGC CTTCCCCCCC 3029
AAAAAGATTG TTCTTCATGC AGAACATACG GCAGTCAACA AAGGGAGACC TGGGTCCAGG 3089
TGTCCAAGTC ACTTATTTG AGTAAATTAG CAATGAAAGA ATGCCATGGA ATCCCTGCCC 3149
AAATACCTCT GCTTATGATA TTGTAGAATT TGATATAGAG TTGTATCCA TTAAAGGAGT 3209
AGGATGTAGT AGGAAAGTAC TAAAAACAAA CACACAAACA GAAAACCTC TTTGCTTTGT 3269
AAGGTGGTTC CTAAGATAAT GTCAGTGCAA TGCTGGAAAT AATATTAAAT ATGTGAAGGT 3329
TTTAGGCTGT GTTTTCCCCT CCTGTTCTTT TTTTCTGCCA GCCCTTTGTC ATTTTGCAG 3389
GTCAATGAAT CATGTAGAAA GAGACAGGAG ATGAACTAG AACCAGTCCA TTTTGCCCT 3449
TTTTTTATTT TCTGGTTTG GTAAAAGATA CAATGAGGTA GGAGGTTGAG ATTTATAAAT 3509
GAAGTTTAAAT AAGTTTCTGT AGCTTTGATT TTTCTTTTC ATATTTGTTA TCTTGATAA 3569
GCCAGAATTG GCCTGTAAAA TCTACATATG GATATTGAAG TCTAAATCTG TTCAACTAGC 3629
TTACACTAGA TGGAGATATT TTCATATTCA GATACACTGG AATGTATGAT CTAGCCATGC 3689

GTAATATAGT CAAGTGTGTTG AAGGTATTTA TTTTAAATAG CGTCTTTAGT TGTGGACTGG 3749
 TTCAAGTTTT TCTGCCAATG ATTTCTTCAA ATTTATCAAA TATTTTCCCA TCATGAAGTA 3809
 AAATGCCCTT GCAGTCACCC TTCCTGAAGT TTGAACGACT CTGCTGTTTT AAACAGTTTA 3869
 AGCAAATGGT ATATCATCTT CCGTTTACTA TGTAGCTTAA CTGCAGGCTT ACGCTTTTGA 3929
 GTCAGCGGCC AACTTTATTG CCACCTTCAA AAGTTTATTA TAATGTTGTA AATTTTACT 3989
 TCTCAAGGTT AGCATACTTA GGAGTTGCTT CACAATTAGG ATTCAGGAAA GAAAGAACTT 4049
 CAGTAGGAAC TGATTGGAAT TTAATGATGC AGCATTCAAT GGGTACTAAT TTCAAAGAAT 4109
 GATATTACAG CAGACACACA GCAGTTATCT TGATTTTCTA GGAATAATTG TATGAAGAAT 4169
 ATGGCTGACA ACACGGCCTT ACTGCCACTC AGCGGAGGCT GGACTAATGA ACACCCTACC 4229
 CTTCTTTCCT TTCCTCTCAC ATTTTCATGAG CGTTTTGTAG GTAACGAGAA AATTGACTTG 4289
 CATTTGCATT ACAAGGAGGA GAAACTGCCA AAGGGGATGA TGGTGGAAGT TTTGTTCTGT 4349
 CTAATGAAGT GAAAAATGAA AATGCTAGAG TTTTGTGCAA CATAATAGTA GCAGTAAAAA 4409
 CCAAGTGAAG AGTCTTTCCA AAAGTGTGTT AAGAGGGCAT CTGCTGGGAA ACGATTTGAG 4469
 GAGAAGGTAC TAAATTGCTT GGTATTTTCC GTAG GA ACC CCA GAG CGA AAT ACA 4523

Gly Thr Pro Glu Arg Asn Thr

115

GTT TGC AAA AGA TGT CCA GAT GGG TTC TTC TCA AAT GAG ACG TCA TCT 4571
 Val Cys Lys Arg Cys Pro Asp Gly Phe Phe Ser Asn Glu Thr Ser Ser
 120 125 130 135

AAA GCA CCC TGT AGA AAA CAC ACA AAT TGC AGT GTC TTT GGT CTC CTG 4619
 Lys Ala Pro Cys Arg Lys His Thr Asn Cys Ser Val Phe Gly Leu Leu
 140 145 150

CTA ACT CAG AAA GGA AAT GCA ACA CAC GAC AAC ATA TGT TCC GGA AAC 4667

Leu Thr Gln Lys Gly Asn Ala Thr His Asp Asn Ile Cys Ser Gly Asn

155

160

165

AGT GAA TCA ACT CAA AAA TGT GGA ATA G GTAATTACAT TCCAAAATAC 4715

Ser Glu Ser Thr Gln Lys Cys Gly Ile

170

175

GTCTTTGTAC GATTTTGTAG TATCATCTCT CTCTCTGAGT TGAACACAAG GCCTCCAGCC 4775
 ACATTCTTGG TCAAACCTTAC ATTTTCCCTT TCTTGAATCT TAACCAGCTA AGGCTACTCT 4835
 CGATGCATTA CTGCTAAAGC TACCACTCAG AATCTCTCAA AAACCTCATCT TCTCACAGAT 4895
 AACACCTCAA AGCTTGATTT TCTCTCCTTT CACACTGAAA TCAAATCTTG CCCATAGGCA 4955
 AAGGGCAGTG TCAAGTTTGC CACTGAGATG AAATTAGGAG AGTCCAAACT GTAGAATTCA 5015
 CGTTGTGTGT TATTACTTTC ACGAATGTCT GTATTATTAA ETAAAGTATA TATTGGCAAC 5075
 TAAGAAGCAA AGTGATATAA ACATGATGAC AAATTAGGCC AGGCATGGTG GCTTACTCCT 5135
 ATAATCCCAA CATTTTGGGG GGCCAAGGTA GGCAGATCAC TTGAGGTCAG GATTTCAAGA 5195
 CCAGCCTGAC CAACATGGTG AAACCTTGTC TCTACTAAAA ATACAAAAAT TAGCTGGGCA 5255
 TGGTAGCAGG CACTTCTAGT ACCAGCTACT CAGGGCTGAG GCAGGAGAAT CGCTTGAACC 5315
 CAGGAGATGG AGGTTGCAGT GAGCTGAGAT TGTACCACTG CACTCCAGTC TGGGCAACAG 5375
 AGCAAGATTT CATCACACAC ACACACACAC ACACACACAC ACACATTAGA AATGTGTACT 5435
 TGGCTTTGTT ACCTATGGTA TTAGTGCATC TATTGCATGG AACTTCCAAG CTACTCTGGT 5495
 TGTGTTAAGC TCTTCATTGG GTACAGGTCA CTAGTATTAA GTTCAGGTTA TTCGGATGCA 5555
 TTCCACGGTA GTGATGACAA TTCATCAGGC TAGTGTGTGT GTTCACCTTG TCACTCCCAC 5615
 CACTAGACTA ATCTCAGACC TTCACTCAA GACACATTAC ACTAAAGATG ATTTGCTTTT 5675
 TTGTGTTTAA TCAAGCAATG GTATAAACCA GCTTGACTCT CCCCCAACAG TTTTTCGTAC 5735
 TACAAAGAAG TTTATGAAGC AGAGAAATGT GAATTGATAT ATATATGAGA TTCTAACCCA 5795
 GTTCCAGCAT TGTTTCATTG TGTAATTGAA ATCATAGACA AGCCATTTTA GCCTTTGCTT 5855

TCTTATCTAA AAAAAAAAAA AAAAAAATGA AGCAAGGGGT ATTAAAAGGA GTGATCAAAT 5915
 TTTAACATTG TCTTTAATTA ATTCATTTTT AATTTTACTT TTTTTCATTT ATTGTGCACT 5975
 TACTATGTGG TACTGTGCTA TAGAGGCTTT AACATTTATA AAAACACTGT GAAAGTTGCT 6035
 TCAGATGAAT ATAGGTAGTA GAACGGCAGA ACTAGTATTC AAAGCCAGGT CTGATGAATC 6095
 CAAAAACAAA CACCCATTAC TCCCATTTTC TGGGACATAC TTA CTCTACC CAGATGCTCT 6155
 GGGCTTTGTA ATGCCTATGT AAATAACATA GTTTTATGTT TGGTTATTTT CCTATGTAAT 6215
 GTCTACTTAT ATATCTGTAT CTATCTCTTG CTTTGTTTCC AAAGGTAAAC TATGTGTCTA 6275
 AATGTGGGCA AAAAATAACA CACTATTCCA AATTACTGTT CAAATTCCTT TAAGTCAGTG 6335
 ATAATTATTT GTTTTGACAT TAATCATGAA GTTCCCTGTG GGTACTAGGT AAACCTTTAA 6395
 TAGAATGTTA ATGTTTGTAT TCATTATAAG AATTTTTGGC TGTACTTAT TTACAACAAT 6455
 ATTTCACTCT AATTAGACAT TTA CTAACT TTCTCTTGAA AACAATGCCC AAAAAAGAAC 6515
 ATTAGAAGAC ACGTAAGCTC AGTTGGTCTC TGCCACTAAG ACCAGCCAAC AGAAGCTTGA 6575
 TTTTATTCAA ACTTTGCATT TTAGCATATT TTATCTTGGA AAATTCAATT GTGTTGGTTT 6635
 TTTGTTTTTG TTTGTATTGA ATAGACTCTC AGAAATCCAA TTGTTGAGTA AATCTTCTGG 6695
 GTTTTCTAAC CTTTCTTAG AT GTT ACC CTG TGT GAG GAG GCA TTC TTC AGG 6747

Asp Val Thr Leu Cys Glu Glu Ala Phe Phe Arg

180

185

TTT GCT GTT CCT ACA AAG TTT ACG CCT AAC TGG CTT AGT GTC TTG GTA 6795
 Phe Ala Val Pro Thr Lys Phe Thr Pro Asn Trp Leu Ser Val Leu Val

190

195

200

GAC AAT TTG CCT GGC ACC AAA GTA AAC GCA GAG AGT GTA GAG AGG ATA 6843
 Asp Asn Leu Pro Gly Thr Lys Val Asn Ala Glu Ser Val Glu Arg Ile

205

210

215

AAA CGG CAA CAC AGC TCA CAA GAA CAG ACT TTC CAG CTG CTG AAG TTA 6891

Lys Arg Gln His Ser Ser Gln Glu Gln Thr Phe Gln Leu Leu Lys Leu

220

225

230

235

TGG AAA CAT CAA AAC AAA GAC CAA GAT ATA GTC AAG AAG ATC ATC CAA G 6940

Trp Lys His Gln Asn Lys Asp Gln Asp Ile Val Lys Lys Ile Ile Gln

240

245

250

GTATGATAAT CTAAAATAAA AAGATCAATC AGAAATCAAA GACACCTATT TATCATAAAC 7000

CAGGAACAAG ACTGCATGTA TGTTTAGTTG TGTGGATCTT GTTCCCTGT TGGAATCATT 7060

GTTGGACTGA AAAAGTTTCC ACCTGATAAT GTAGATGTGA TTCCACAAAC AGTTATACAA 7120

GGTTTTGTTT TCACCCCTGC TCCCAGTTT CCTTGTAAG TATGTTGAAC ACTCTAAGAG 7180

AAGAGAAATG CATTGAAGG CAGGGCTGTA TCTCAGGGAG TCGCTTCCAG ATCCCTTAAC 7240

GCTTCTGTAA GCAGCCCCTC TAGACCACCA AGGAGAAGCT CTATAACCAC TTTGTATCTT 7300

ACATTGCACC TCTACCAAGA AGCTCTGTTG TATTTACTTG GTAATTCTCT CCAGGTAGGC 7360

TTTTCGTAGC TTACAAATAT GTTCTTATTA ATCCTCATGA TATGGCCTGC ATTAAAATTA 7420

TTTTAATGGC ATATGTTATG AGAATTAATG AGATAAAATC TGAAAAGTGT TTGAGCCTCT 7480

TGTAGGAAAA AGCTAGTTAC AGCAAAATGT TCTCATCTCT TATAAGTTTA TATAAAGATT 7540

CTCCTTTAGA AATGGTGTGA CAGAGAAACA GAGAGAGATA GGGAGAGAAG TGTGAAAGAA 7600

TCTGAAGAAA AGGAGTTTCA TCCAGTGTGG ACTGTAAGCT TTACGACACA TGATGGAAAG 7660

AGTTCTGACT TCAGTAAGCA TTGGGAGGAC ATGCTAGAAG AAAAAGGAAG AAGAGTTTCC 7720

ATAATGCAGA CAGGGTCAGT GAGAAATTCA TTCAGGTCCT CACCAGTAGT TAAATGACTG 7780

TATAGTCTTG CACTACCCTA AAAAATTCA AGTATCTGAA ACCGGGGCAA CAGATTTTAG 7840

GAGACCAACG TCTTTGAGAG CTGATTGCTT TTGCTTATGC AAAGAGTAAA CTTTATGTT 7900

TTGAGCAAAC CAAAAGTATT CTTTGAACGT ATAATTAGCC CTGAAGCCGA AAGAAAAGAG 7960

AAAATCAGAG ACCGTTAGAA TTGGAAGCAA CCAAAATCCC TATTTTATAA ATGAGGACAT 8020

TTTAACCCAG AAAGATGAAC CGATTTGGCT TAGGGCTCAC AGATACTAAG TGACTCATGT 8080
 CATTAAATAGA AATGTTAGTT CCTCCCTCTT AGGTTTGTAC CCTAGCTTAT TACTGAAATA 8140
 TTCTCTAGGC TGTGTGTCTC CTTTAGTTCC TCGACCTCAT GTCTTTGAGT TTTCAGATAT 8200
 CCTCCTCATG GAGGTAGTCC TCTGGTGCTA TGTGTATTCT TTAAAGGCTA GTTACGGCAA 8260
 TTAACCTTATC AACTAGCGCC TACTAATGAA ACTTTGTATT ACAAAGTAGC TAACCTGAAT 8320
 ACTTTCCTTT TTTTCTGAAA TGTTATGGTG GTAATTTCTC AACTTTTTTC TTAGAAAAC 8380
 GAGAGTGATG TGTCTTATTT TCTACTGTTA ATTTTCAAAA TTAGGAGCTT CTTCCAAAGT 8440
 TTTGTTGGAT GCCAAAAATA TATAGCATAT TATCTTATTA TAACAAAAAA TATTTATCTC 8500
 AGTTCTTAGA AATAAATGGT GTCACTTAAC TCCCTCTCAA AAGAAAAGGT TATCATTGAA 8560
 ATATAATTAT GAAATTCTGC AAGAACCCTT TGCCTCACGC TTGTTTTATG ATGGCATTGG 8620
 ATGAATATAA ATGATGTGAA CACTTATCTG GGCTTTTGCT TTATGCAG AT ATT GAC 8676

Asp Ile Asp

CTC TGT GAA AAC AGC GTG CAG CGG CAC ATT GGA CAT GCT AAC CTC ACC 8724
 Leu Cys Glu Asn Ser Val Gln Arg His Ile Gly His Ala Asn Leu Thr
 255 260 265 270

TTC GAG CAG CTT CGT AGC TTG ATG GAA AGC TTA CCG GGA AAG AAA GTG 8772
 Phe Glu Gln Leu Arg Ser Leu Met Glu Ser Leu Pro Gly Lys Lys Val
 275 280 285

GGA GCA GAA GAC ATT GAA AAA ACA ATA AAG GCA TGC AAA CCC AGT GAC 8820
 Gly Ala Glu Asp Ile Glu Lys Thr Ile Lys Ala Cys Lys Pro Ser Asp
 290 295 300

CAG ATC CTG AAG CTG CTC AGT TTG TGG CGA ATA AAA AAT GGC GAC CAA 8868

Gln Ile Leu Lys Leu Leu Ser Leu Trp Arg Ile Lys Asn Gly Asp Gln

305

310

315

GAC ACC TTG AAG GGC CTA ATG CAC GCA CTA AAG CAC TCA AAG ACG TAC 8916

Asp Thr Leu Lys Gly Leu Met His Ala Leu Lys His Ser Lys Thr Tyr

320

325

330

CAC TTT CCC AAA ACT GTC ACT CAG AGT CTA AAG AAG ACC ATC AGG TTC 8964

His Phe Pro Lys Thr Val Thr Gln Ser Leu Lys Lys Thr Ile Arg Phe

335

340

345

350

CTT CAC AGC TTC ACA ATG TAC AAA TTG TAT CAG AAG TTA TTT TTA GAA 9012

Leu His Ser Phe Thr Met Tyr Lys Leu Tyr Gln Lys Leu Phe Leu Glu

355

360

365

ATG ATA GGT AAC CAG GTC CAA TCA GTA AAA ATA AGC TGC TTA 9054

Met Ile Gly Asn Gln Val Gln Ser Val Lys Ile Ser Cys Leu

370

375

380

TAACTGGAAA TGGCCATTGA GCTGTTTCCT CACAATTGGC GAGATCCCAT GGATGAGTAA 9114

ACTGTTTCTC AGGCACTTGA GGCTTTCAGT GATATCTTTC TCATTACCAG TGACTAATTT 9174

TGCCACAGGG TACTAAAAGA AACTATGATG TGGAGAAAGG ACTAACATCT CCTCCAATAA 9234

ACCCCAAATG GTTAATCCAA CTGTCAGATC TGGATCGTTA TCTACTGACT ATATTTTCCC 9294

TTATTACTGC TTGCAGTAAT TCAACTGGAA ATTAAAAAAA AAAAAGTAGA CTCCACTGGG 9354

CCTTACTAAA TATGGGAATG TCTAACTTAA ATAGCTTTGG GATTCCAGCT ATGCTAGAGG 9414

CTTTTATTAG AAAGCCATAT TTTTCTGT AAAAGTTACT AATATATCTG TAACACTATT 9474

ACAGTATTGC TATTTATATT CATTCAAGATA TAAGATTTGG ACATATTATC ATCCTATAAA 9534
 GAAACGGTAT GACTTAATTT TAGAAAGAAA ATTATATTCT GTTTATTATG ACAAATGAAA 9594
 GAGAAAATAT ATATTTTAA TGGAAAGTTT GTAGCATTTC TCTAATAGGT ACTGCCATAT 9654
 TTTTCTGTGT GGAGTATTTT TATAATTTTA TCTGTATAAG CTGTAATATC ATTTTATAGA 9714
 AAATGCATTA TTTAGTCAAT TGTTTAATGT TGGAAAACAT ATGAAATATA AATTATCTGA 9774
 ATATTAGATG CTCTGAGAAA TTGAATGTAC CTTATTTAAA AGATTTTATG GTTTTATAAC 9834
 TATATAAATG ACATTATTAA AGTTTTCAAA TTATTTTAA TTGCTTTCTC TGTGCTTTT 9894
 ATTT 9898

Sequence number: 3

Length of sequence: 401

Sequence Type: amino acid

Strandedness: single stranded

Topology: linear

Molecular type: protein

Sequence:

Met	Asn	Asn	Leu	Leu	Cys	Cys	Ala	Leu	Val	Phe	Leu	Asp	Ile	Ser
-20					-15					-10				
Ile	Lys	Trp	Thr	Thr	Gln	Glu	Thr	Phe	Pro	Pro	Lys	Tyr	Leu	His
-5					1					5				
Tyr	Asp	Glu	Glu	Thr	Ser	His	Gln	Leu	Leu	Cys	Asp	Lys	Cys	Pro
10					15					20				
Pro	Gly	Thr	Tyr	Leu	Lys	Gln	His	Cys	Thr	Ala	Lys	Trp	Lys	Thr
25					30					35				
Val	Cys	Ala	Pro	Cys	Pro	Asp	His	Tyr	Tyr	Thr	Asp	Ser	Trp	His
40					45					50				

Ile Gln Asp Ile Asp Leu Cys Glu Asn Ser Val Gln Arg His Ile		
250	255	260
Gly His Ala Asn Leu Thr Phe Glu Gln Leu Arg Ser Leu Met Glu		
265	270	275
Ser Leu Pro Gly Lys Lys Val Gly Ala Glu Asp Ile Glu Lys Thr		
280	285	290
Ile Lys Ala Cys Lys Pro Ser Asp Gln Ile Leu Lys Leu Leu Ser		
295	300	305
Leu Trp Arg Ile Lys Asn Gly Asp Gln Asp Thr Leu Lys Gly Leu		
310	315	320
Met His Ala Leu Lys His Ser Lys Thr Tyr His Phe Pro Lys Thr		
325	330	335
Val Thr Gln Ser Leu Lys Lys Thr Ile Arg Phe Leu His Ser Phe		
340	345	350
Thr Met Tyr Lys Leu Tyr Gln Lys Leu Phe Leu Glu Met Ile Gly		
355	360	365
Asn Gln Val Gln Ser Val Lys Ile Ser Cys Leu		
370	375	380

Sequence number: 4

Length of sequence: 1206

Sequence Type: nucleic acid

Strandedness: single stranded

Topology: linear

Molecular type: cDNA

Sequence:

```

ATGAACAAC T GCTGTGCTG CGCGCTCGTG TTTCTGGACA TCTCCATTAA GTGGACCACC 60
CAGGAAACGT TTCCTCCAAA GTACCTTCAT TATGACGAAG AAACCTCTCA TCAGCTGTTG 120
TGTGACAAAT GTCCTCCTGG TACCTACCTA AAACAACACT GTACAGCAAA GTGGAAGACC 180
GTGTGCGCCC CTTGCCCTGA CCACTACTAC ACAGACAGCT GGCACACCAG TGACGAGTGT 240
CTATACTGCA GCCCCGTGTG CAAGGAGCTG CAGTACGTCA AGCAGGAGTG CAATCGCACC 300
CACAACCGCG TGTGCGAATG CAAGGAAGGG CGCTACCTTG AGATAGAGTT CTGCTTGAAA 360
CATAGGAGCT GCCCTCCTGG ATTTGGAGTG GTGCAAGCTG GAACCCCAAG GCGAAATACA 420
GTTTGCAAAA GATGTCCAGA TGGGTTCTTC TCAAATGAGA CGTCATCTAA AGCACCCCTGT 480
AGAAAACACA CAAATTGCAG TGTCTTTGGT CTCCTGCTAA CTCAGAAAGG AAATGCAACA 540
CACGACAACA TATGTTCCGG AAACAGTGAA TCAACTCAAA AATGTGGAAT AGATGTTACC 600
CTGTGTGAGG AGGCATTCTT CAGGTTTGCT GTTCCTACAA AGTTTACGCC TAACTGGCTT 660
AGTGTCTTGG TAGACAATTT GCCTGGCACC AAAGTAAACG CAGAGAGTGT AGAGAGGATA 720
AAACGGCAAC ACAGCTCACA AGAACAGACT TTCCAGCTGC TGAAGTTATG GAAACATCAA 780
AACAAAGACC AAGATATAGT CAAGAAGATC ATCCAAGATA TTGACCTCTG TGAAAACAGC 840
GTGCAGCGGC ACATTGGACA TGCTAACCTC ACCTTCGAGC AGCTTCGTAG CTTGATCGAA 900
AGCTTACCGG GAAAGAAAGT GGGAGCAGAA GACATTGAAA AAACAATAAA GGCATGCAAA 960
CCCAGTGACC AGATCCTGAA GCTGCTCAGT TTGTGGCGAA TAAAAAATGG CGACCAAGAC 1020
ACCTTGAAGG GCCTAATGCA CGCACTAAAG CACTCAAAGA CGTACCACTT TCCCAAAACT 1080
GTCACTCAGA GTCTAAAGAA GACCATCAGG TTCCTTCACA GCTTCACAAT GTACAAATTG 1140
TATCAGAAGT TATTTTTAGA AATGATAGGT AACCAGGTCC AATCAGTAAA AATAAGCTGC 1200
TTATAA 1206

```

CLAIMS:

1. A DNA comprising the nucleotide sequences of the Sequences No. 1 and No. 2 in the Sequence Table.

2. The DNA according to claim 1, wherein the Sequence ID No. 1 includes the first exon of the OCIF gene and the Sequence ID No. 2 includes the second, third, fourth, and fifth exons.

3. A protein exhibiting the activity of inhibiting differentiation and/or maturation of osteoclasts and having the following physicochemical characteristics,

(a) molecular weight (SDS-PAGE):

(i) Under reducing conditions: about 60 kD,

(ii) Under non-reducing conditions: about 60 kD and about 120 kD;

(b) amino acid sequence:

includes an amino acid sequence of the Sequence ID No. 3 in the Sequence Table,

(c) affinity:

exhibits affinity to a cation exchanger and heparin, and

(d) heat stability:

(i) the osteoclastogenesis-inhibitory activity is reduced when treated with heat at 70°C for 10 minutes or at 56°C for 30 minutes,

(ii) the osteoclastogenesis-inhibitory activity is lost when treated with heat at 90°C for 10 minutes.

4. A process for producing a protein exhibiting an

activity of inhibiting differentiation and/or maturation of osteoclasts and having the following physicochemical characteristics,

(a) molecular weight (SDS-PAGE):

(i) Under reducing conditions: about 60 kD,

(ii) Under non-reducing conditions: about 60 kD and about 120 kD;

(b) amino acid sequence:

includes an amino acid sequence of the Sequence ID No. 3 of the Sequence Table,

(c) affinity:

exhibits affinity to a cation exchanger and heparin, and

(d) heat stability:

(i) the osteoclastogenesis-inhibitory activity is reduced when treated with heat at 70°C for 10 minutes or at 56°C for 30 minutes,

(ii) the osteoclastogenesis-inhibitory activity is lost when treated with heat at 90°C for 10 minutes,

the process comprising inserting a DNA including the nucleotide sequences of the sequences No. 1 and No. 2 in the Sequence Table into an expression vector, producing a vector capable of expressing a protein having the above-mentioned physicochemical characteristics and exhibiting the activity of inhibiting differentiation and/or maturation of osteoclasts, and producing this protein by a genetic engineering technique.

1/1

Figure 1

